Skip to content

Vera Therapeutics VERA Shares (Diluted)

Shares (Diluted) at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
256.3M-1.2%
Travere Therapeutics, Inc. logo
Travere Therapeutics, Inc.TVTX
91.9M+4.0%
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
137.6M-3.9%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
24.7M+75.9%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
81.3M+33.1%
Immunome logo
ImmunomeIMNM
113.1M+42.5%

Other financials

Income statement

See full
Operating income-$125.1M-119%
Net income-$121.0M-134%
EPS (diluted)-$1.69-109%

Balance sheet

See full
Cash & equivalents$114.4M+108%
Total debt$75.0M+37.8%
Total equity$499.7M-6.6%
Total assets$621.7M+1.9%

Cash flow

See full
Operating cash flow-$106.5M-95.8%
CapEx$23.0K-87.7%
Free cash flow-$106.5M-95.1%

Valuation

See full
Market cap$2.74B+87.5%
Enterprise value$2.7B+85.0%

Returns & leverage

See full
Return on equity-71.3%+296pp
Debt / equity0.2×0.0×
Current ratio13.6×-14.0×

Where this comes from

Reported directly by Vera Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.

The official record: Vera Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vera Therapeutics's shares (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Vera Therapeutics's shares (diluted)?
Vera Therapeutics (VERA) reported shares (diluted) of 71.5M in Q1 2026.
How has Vera Therapeutics's shares (diluted) changed year-over-year?
Vera Therapeutics's shares (diluted) increased by 12.3% year-over-year, from 63.7M to 71.5M.
What is the long-term trend for Vera Therapeutics's shares (diluted)?
Over 4 years (2021 to 2025), Vera Therapeutics's shares (diluted) has grown at a 53.9% compound annual growth rate (CAGR), from 45.6M to 255.5M.
What does shares (diluted) mean?
The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.